Mosunetuzumab

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells) . Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) [1][2].

Product Specifications

CAS Number

[1905409-39-3]

Product Name Alternative

BTCT-4465A; RG-7828; RO7030816

UNSPSC

12352203

Target

CD20; CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mosunetuzumab.html

Purity

99.05

Solubility

H2O

Smiles

[Mosunetuzumab]

Molecular Weight

(144 kDa)

References & Citations

[1]Lihua E Budde, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40 (5) :481-491.|[2]Gregory Z Ferl, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018 May;11 (3) :296-304.